• linkedin
  • Increase Font
  • Sharebar

    Vitrectomy offers a viable therapeutic option for DME


    In favor of vitrectomy

    Dr. Landers said there is considerable evidence that PPV reduces macular edema in patients with DME. In the DRCR.net Vitrectomy for DME study, central subfield thickness (CST) decreased in more than 90% of patients and was reduced 33% overall, from 412 µm to 278 µm.

    Figure 1: The top graph shows the results of the meta-analysis of 1,800+ cases of vitrectomy for DME in the literature, showing the resulting decreased macular thickness after vitrectomy. The bottom graph outlines the duration of follow-up in these studies, showing the long term, beneficial effect of vitrectomy on macular thickness, up to 30 months in some cases (Images courtesy of Maurice Landers III, MD)

    Furthermore, in a 2013 publication that reviewed data from more than 1,800 patients with DME, Dr. Landers and colleagues found the vast majority of patients achieved a durable decrease in macular thickness, showing persistence through follow-up periods that extended up to 30 months.

    Doubt that PPV has benefit for treating DME may exist because in the DRCR.net Vitrectomy for DME study, it was not associated with improvement in visual acuity. Dr. Landers suggested, however, that selection bias may explain that study’s outcome.

    “We know from other studies that vision of patients with DME never improves without an associated decrease in CST,” Dr. Landers said. “The DRCR.net study, however, recruited patients who had failed all other treatments and they likely had irreversible retinal damage that limited their potential for vision improvement even after successful reduction of their macular edema.”



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';